Treatment of Depression Using Agents that Block Binding of IL-6 to IL-6 Receptor
AssigneeJanssen Biotech, Inc.
InventorsGuang Chen, Yu Sun, Dai Wang, Gayle Wittenberg
Life of this patent
Estimating the term…
Loading patent…
AssigneeJanssen Biotech, Inc.
InventorsGuang Chen, Yu Sun, Dai Wang, Gayle Wittenberg
Estimating the term…
A method for treating depression or fatigue in a subject comprises administering an agent that blocks binding of IL-6 to IL-6 receptor, for example, an anti-IL-6 antibody or an antigen-binding fragment thereof that may comprise a heavy chain variable region and a light chain variable region of SEQ ID NO:99 and SEQ ID NO:97, respectively or a heavy chain variable region and a light chain variable region of SEQ ID NO:139 and SEQ ID NO:140, respectively. In addition, a method for determining responsiveness of an individual having depression to treatment with IL-6 antibody or antigen-binding fragment thereof, comprises: (a) measuring the amount of soluble IL-6 receptor (sIL-6R) in a biological sample from the subject; (b) providing a threshold value correlating the amount of sIL-6R and responsiveness; (c) comparing the amount of sIL-6R to the threshold value to determine responsiveness; and (d) treating the individual with an agent that blocks binding of IL-6 to IL-6 receptor.
A method for treating depression or fatigue in a subject comprising administering to the subject an effective amount of a pharmaceutical composition comprising an agent that blocks binding of IL-6 to IL-6 receptor.
A method for determining responsiveness of an individual having depression to the treatment with IL-6 antibody or a fragment thereof, comprising:
Dependencies are inferred from the claim text.